Tobacco dependence: Fundamental concepts and recent advances

Current Opinion in Psychiatry

Volumn 11, Issue 3, 1998, Pages 259-263

  Henningfield, Jack E ^a,b   Gopalan, Lakshmi ^b   Shiffman, Saul ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PINNEY ASSOCIATES   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM;

CIGARETTE SMOKING; COMORBIDITY; DRUG DEPENDENCE; DRUG WITHDRAWAL; HIGH RISK POPULATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; REVIEW; RISK ASSESSMENT; SEIZURE; SLEEP DISORDER; SMOKING CESSATION; TOBACCO; TRANSDERMAL DRUG ADMINISTRATION; XEROSTOMIA;

EID: 0031918049     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-199805000-00004     Document Type: Review

References (49)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd edn. Washington DC: American Psychiatric Association; 1980.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. edn. Washington DC: American Psychiatric Association; 1987
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. Washington DC: American Psychiatric Association; 1994.
4. Henningfield JE. Nicotine medication for smoking cessation. N Engl J Med 1995; 333:1196-1203.
5. Henningfield JE, Schuh LM, Jarvik ME, Pharmacological therapies: nicotine addiction. In; edited by Miller NS, Gold MS. Psycopharmacological therapies for drug and alcohol addictions. New York: Marcel Dekker. Inc: 1995, pp. 239-264.
6. American Psychiatric Association. Practice guideline for the treatment of patients with nicotine dependence. Am J Psychiatry 1996; 153 (suppl) 1-31. This clinical guideline includes diagnostic issues and discussions of psychiatric comorbidities that will be especially relevant to psychiatric and other behavioral health professionals.
7. Fiore MC, Bailey WC, Cohen SJ, Dorfman S, Goldstein MG, Gritz ER. et al. Smoking cessation: clinical practice guideline. Rockville, MD: Agency for Health Care Policy and Research; AHCPR Publication No. 96-0692, No. 18; 1996. This guideline can serve as the foundation for scientific evidence based clinical approaches to treat nicotine dependence in general practice settings with coverage of a wide range of treatment issues.
8. U.S. Preventive Services Task Force: Counseling to prevent tobacco use In; Guide to clinical preventive services. 2nd edn. Baltimore: Williams & Wilkins: 1996, pp. 597-609.
9. Henningfield JE, Shiftman S. Practice guideline for the treatment of patients with nicotine dependence. Abstr Clin Care Guidelines 1997; 9:27.
10. Shiftman S, Engberg JB, Paty JA, Perz WG, Gnys M, Kassel JD, Hickcox M. A day at a time: predicting smoking lapse from daily urge. J Abnorm Psychol 1997; 106:104-116. This paper provides a clinically relevant discussion and analysis of the intervention between craving for a cigarette and relapse to smoking.
11. Kessler DA, Witt AM, Barnett PS, Zeller MR, Natanblut SL, Wilkenfeld JP. et al. The Food and Drug Administration's regulation of tobacco products N Engl J Med 1996; 335:988-993. This paper summarizes the scientific and legal basis for the Food and Drug Administrations 1996 rule which asserted jurisdiction over cigarette and smokeless tobacco products.
12. Kessler DA, Natanblut SL, Wilkenfeld JP, Lorraine CC, Mayl SL. Bernstein IBG, Thompson L. Nicotine addiction, a pediatrie disease. J Pediatr 1997; 130:518-524. This paper describes the scientific, regulatory and public health implications of the characterization of nicotine addiction as a pediatrie disease.
13. Prokhorov AV, Pallonen UE, Fava JL, Ding L, Niaura R. Measuring nicotine dependence among high-risk adolescent smokers. Addict Behav 1996; 21:117-127.
14. Smith TA, House RF, Croghan IT, Gauvin TR, Colligan RC, Offord KP. et al. Nicotine patched therapy in adolescent smokers. Pediatrics 1996; 98:659-667.
15. Food and Drug Administration: 21 CFR Part 801. et al. Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents; final rule. Federal Register. Washington D.C.: Department of Health and Human Services, 61; August 28 1996; 44396-45318.
16. Lerman C, Main D, Audrain J, Caporaso N, Boyd NR, Bowman ED, Shields PG. Depression and self medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychology 1998, 17:56-62.
17. Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC. Smoking and major depression - a causal analysis. Arch Gen Psychiatry 1993; 50:36-43.
18. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolec Psychiatry 1997; 36:37-44.
19. True WR, Heath AC, Scherrer JF, Waterman B, Goldberg J, Lin N, et al. Genetic and environmental contributions to smoking. Addiction 1997; 92:1277-1287.
20. Newhouse PA, Potter A, Levin ED. Nicotinic system involvement in Alzheimers and Parkinson's diseases-implications for therapeutics. Drugs Aging 1997; 11:206-228.
21. Pomerleau CS. Co-factors for smoking and evolutionary psychobiology. Addiction 1997; 92:397-408.
22. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A 1996; 93:14065-14069.
23. Heishman SJ. What aspects of human performance are truly enhanced by nicotine? Addiction 1998; 93:317-320.
24. Borrelli B, Niaura R, Keuthen NJ, Goldstein MG, Depue JD, Murphy C, Abrams DB. Development of major depressive disorder during smoking cessation treatment. J Clin Psychiatry 1996; 57:534-538. This study provided scientifically based insights relevant to the prognosis and management of patients with histories of major depression during smoking cessation therapy.
25. Deleon J. Smoking and vulnerability for schizophrenia. Schizophr Bull 1996; 22:405-409.
26. Kick SD, Cooley DD. Depressive, not anxiety, symptoms are associated with current cigarette smoking among university internal medical patients. Psychosomatics 1997; 38:132-139.
27. Madden PAF, Bucholz KK, Dinwiddie SH, Slutske WS, Bierut LJ, Statham DJ, et al. Nicotine withdrawal in women. Addiction 1997; 92:889-902.
28. Svikis D, Henningfield JE, Gazaway P, Huggins G, Sosnow K, Hranicka J, et al. Tobacco use for identifying pregnant women at risk of substance abuse. J Reprod Med 1997; 42:299-302.
29. Hughes JR. The future of smoking cessation therapy in the United States. Addiction 1996; 91:1797-1802.
30. Covey LS, Glassman AH, Stetner F. Major depression following smoking cessation. Am J Psychiatry 1996; 154:263-265. This is an important review and evaluation of the association between tobacco and depression and of the factors associated with the emergence of depression during smoking cessation.
31. Glassman AH, Covey LS. Nicotine and major depression. In: Optiz K, (editor). Nicotine as a therapeutic agent. Stuttgart: Immunity and Evironment 1997; 10:15-21.
32. Hughes JR. Treating nicotine dependence in mental health settings. J Prac Psych Behav Health 1997; 250-254.
33. Glover ED, Leischow SJ, Rennard SI, Glover PN, Daughton D, Quiring JN, et al. A smoking cessation trial with lobeline sulfate: a pilot study. Am J Health Behav 1998; 22:62-74.
34. Shiftman S, Gitchell J, Strecher V. Real-world efficacy of computer-tailored smoking cessation material as a supplement to nicotine replacement. Abstract presented at the 10th World Conference on Tobacco or Health. Beijing, China. 24-28 August 1997.
35. Morbidity and Mortality Weekly Report: Impact of promotion of the great American smokeout and availability of over-the-counter nicotine medications, 1996. Morbid Mortal Week Rep 1997; 46:867-871.
36. Shiftman S, Gitchell J, Pinney J, Burton SL, Kemper KE, Lara EA. Public health benefit of over-the-counter nicotine medications. Tobacco Control 1997; 6:306-310. This paper summarizes the medical and public health implications of over-the-counter nicotine gum and patch.
37. Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, Steinberg C. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995; 90:1671-1682.
38. Gourtay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine Clin Pharmacol Ther 1997; 62:453-463.
39. Schneider NG, Lunell E, Olmstead RE, Fagerstrom KO. Clinical pharmacokinetics of nasal nicotine delivery - a review and comparison to other nicotine systems. Clin Pharmacokinet 1996; 31:65-80.
40. Lunell E, Molander L, Andersson SB. Temperature dependency of the release and bioavailability of nicotine from a nicotine vapor inhaler; in vitro/in vivo correlation. Eur J Clin Pharmacol 1997; 52:495-500.
41. Schneider NG, Olmstead H, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo controlled trial. Addiction 1996; 91:1293-1306.
42. Lunell E, Bergstrom M, Antoni G, Langstrom B, Nordberg A. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography - letter to the editor. Clin Pharmacol Ther 1996; 59:593-594.
43. Schuh KJ, Schuh LM, Henningfield JE, Stitzer ML. Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology 1997; 130:352-361
44. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and mania. In: Molinoff PB, Ruddon RW, (editors). Goodman and Oilman's The pharmacological basis of therapeutics. 9th edn. New York: McGraw-Hill; 1996, pp. 431-459.
45. Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195-1202. This was the first published clinical trial on the currently marketed form of bupropion for smoking cessation.
46. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG. et al. The safely of transdermal nicotine as an aid to to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335:1792-1798. This paper described a study and included a clinically relevant discussion of the potential risks and benefits of nicotine replacement in patients with cardiac disease.
47. Mahmarian JJ, Moye LA, Nasser GA, Nagueh SF, Bloom MF, Benowitz NL, et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol 1997; 38:125-130. This group evaluated and reviewed the effects of transdermal nicotine compared with cigarette smoking on cardiovascular function and provided a psychological basis for why transdermal nicotine is so much safer than cigarette smoking.
48. Benowitz NL. Nicotine replacement therapy: what has been accomplished-can we do better? Drugs 1993; 45:157-170.
49. Dale LC, Olsen DA, Patten CA, Schroeder DR, Croghan IT, Hurt RD. et al. Predictors of smoking cessation among elderly smokers treated for nicotine dependence. Tobacco Control 1997; 6:181-187.